PRLog (Press Release) - Jun 03, 2012 - Immune Response BioPharma, Inc. Plans Listing on German Exchanges to Fund Blockbuster MS Drug NeuroVax which is a first in class and best in class Multiple Sclerosis Vaccine.
IRBP has decided to pursue a listing on the German Exchanges, we will first list on the Berlin Exchange and then move to the Frankfurt Exchange. NeuroVax is the first MS Vaccine is a first in class and best in class drug that restores deficient FOXP3+ T-Regs which is the key to halting the disease and repairing the damaged T-Cells. NeuroVax has the potential to become treatment of choice for MS patients and do annual sales of north of a billion dollars.
"IRBP will determine the timing, pricing and sale of any shares to be listed on the German Exchanges. Raising sufficient capital and giving investors a liquid investment vehicle will enhance our ability to raise the necessary funds to drive NeuroVax to regulatory and eventual FDA approval. We will continue to seek a corporate partnership for NeuroVax, although we may choose to fund the development costs and own the drug and become the new power in Pharma" IRBP CEO Mr. David Buswell
Immune Response BioPharma, Inc. maybe found on the WorldWide Web @ www.immuneresponsebiopharma.com